Funded Tech Companies
Neukio Biotherapeutics
Headquartered in Shanghai, Neukio Biotherapeutics has funding from Lilly Asia Ventures, Surplus Capital and CD Capital.
Company Overview
Company Name
Neukio Biotherapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
3F, Building 7-5, No. 215 South Fute Road
Shanghai, Undisclosed
CN
Shanghai, Undisclosed
CN
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Established in June 2021 at the Life Science Park of the Shanghai Free Trade Zone, Neukio focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products. The management team has rich cell therapy experience, CEO and other key managers have led the Fosun Kite JV from the start and successfully launched the first CAR-T product Yescarta® commercialization in China (tech transfer, manufacturing, clinical trials and regulatory approval) in less than three years. Supported by renowned VC investors including Lilly Asia Ventures, IDG Capital and Sherpa Capital, with a $40M angel round funding in August 2021.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
9/2/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Wang
VP - R & D
Lei Zhang
Company Investors
- Lilly Asia Ventures
- Surplus Capital
- CD Capital
- IDG Capital Partners
- Alwin Capital
- Sherpa Healthcare Partners
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs